ICAM-1 Antibody in Psorasis Mouse Model
Title: Efficacy of the fully human monoclonal
antibody MOR102 (#5) against intercellular adhesion molecule 1
in the psoriasis-severe combined immunodeficient mouse model.
Authors: Boehncke WH, et al.
Publication: Br J Dermatol. 2005 Oct;153(4):758-66.
Intercellular adhesion molecule 1 (ICAM-1) is involved in leukocyte
or white blood cell adhesion, extravasation (forcing of blood
or lymph from a blood or lymph vessel out into the surrounding
tissue), and lymphocyte activation. Because of this, the authors
suggested that targeting ICAM-1 might work as treatment for psoriasis.
The authors selected human monoclonal antibody MOR102(#5), which
was shown to interfere with lymphocyte activation and adhesion
in test tubes, as well as for its effectiveness against psoriasis
in mouse (using psoriasis-severe combined immunodeficient mouse
model).
The authors confirmed the ability of MOR102(#5) to inhibit lymphocyte
adhesion to ICAM-5, and also found that MOR102(#5) reduced lymphocyte
proliferation in cell cultures. When injected into psoriatic lesion
grafted onto mice (at a dosage of 10 mg/kg, every other day for
4 days), the authors found:
- Reduction in the epidermal thickness
- Reconstitution of the keratin layer of the skin
- Reduction in inflammation.
The authors suggested that the therapeutic activity of MOR102(#5)
antibody might be due to targeting of ICAM-1 on skin cells that
produce keratin and the prevention of T-cell activation. Based
on this experiment, fully human monoclonal antibody MOR102(#5)
should be clinically tested as treatment for psoriasis.
Editor’s Note: lymphocytes are cells formed in
the lymphoid tissue, and are a component of white blood cells.
These cells are involved in the body’s immune response.
Keratin is a tough, insoluble protein that is a major component
of hair and nails.
